Visudyne 15 mg/1 (Verteporfin for Injection INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION) 15 mg/1

Verteporfin, the active ingredient in Visudyne, is a photosensitizer. After activation by red light (689 nm), it generates reactive oxygen species that cause selective occlusion of neovascular tissue in the eye. This process helps to block the abnormal blood vessels, reducing leakage and slowing vision loss.

The dosage of Visudyne is determined by a healthcare professional based on the patient's condition and response to treatment. It is important to follow the prescribed dosage and administration instructions provided by your doctor.

Visudyne is classified as a pregnancy category C drug, meaning it should be used during pregnancy only if the potential benefits outweigh the risks. It is not known whether Verteporfin is excreted in human milk, so caution should be exercised when administering to nursing mothers. Always consult your healthcare provider for personalized advice.

To order Visudyne from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team will then reply with pricing, availability, shipping, and the import paperwork.

Visudyne is one of the treatments available for wet age-related macular degeneration (AMD). It is particularly effective for the predominantly classic form of choroidal neovascularization (CNV). Other treatments may include anti-VEGF injections, which work by blocking the growth of abnormal blood vessels. The choice of treatment depends on the specific condition and the patient's response.

Visudyne should be stored at room temperature and protected from light. It is important to follow the storage instructions provided with the medication to ensure its effectiveness and safety. Always handle the medication with care and follow the administration guidelines provided by your healthcare professional.

Visudyne is administered by intravenous infusion, usually in the arm, over a 10-minute period. After a few minutes, a laser light is shone on the eye to activate the medication. This procedure is typically performed by a healthcare professional in a clinical setting.

The most serious risks associated with Visudyne include severe decrease in vision, seizures, and signs of an allergic reaction such as difficulty breathing, hives, or swelling of the face, lips, tongue, or throat. If any of these symptoms occur, seek immediate medical attention.

Visudyne should not be used by individuals who have porphyria, are allergic to Verteporfin or any of its components, or have severe liver dysfunction. Always consult your healthcare provider to determine if Visudyne is suitable for you.